Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer. 2012

Sun-Young Kong, and Mi Hwa Han, and Heon-Jong Yoo, and Jong Ha Hwang, and Myong Cheol Lim, and Sang-Soo Seo, and Chong-Woo Yoo, and Jae-Hoon Kim, and Sang-Yoon Park, and Sokbom Kang
Hematologic Malignancies Branch, Research Institute and Hospital, Goyang, Republic of Korea.

BACKGROUND This study was designed to determine whether serum HE4 is an independent prognostic factor in ovarian cancer patients. METHODS We measured HE4 in pretreatment serum samples from 80 women with epithelial ovarian cancer, using an enzyme-linked immunosorbent assay. The results were correlated with clinical data. RESULTS The median serum HE4 level in ovarian cancer patients was 98.7 (range, 80.3-222.8) pg/ml. Elevated serum HE4 levels before therapy significantly correlated with a poorer progression free survival (log-rank test, P = 0.017). Multivariate analysis revealed serum HE4 to be an independent prognostic factor for progression-free survival (P = 0.036). In multivariate regression analysis, high serum HE4 levels significantly correlated with high tumor grade and serous histology (P = 0.004 and 0.017). In addition, high serum HE4 levels were significantly associated with residual tumor size and operative time (P = 0.003 and 0.033). CONCLUSIONS Pretreatment serum HE4 seems to be an additional factor for predicting the outcome of patients with epithelial ovarian cancer. Due to its independence from established prognostic factors, serum HE4 may provide additional prognostic information.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D009375 Neoplasms, Glandular and Epithelial Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue. Epithelial Cell Neoplasms,Glandular Cell Neoplasms,Epithelial Neoplasms,Glandular Neoplasms,Glandular and Epithelial Neoplasms,Neoplasms, Epithelial,Neoplasms, Glandular,Neoplasms, Glandular Epithelial,Cell Neoplasm, Epithelial,Cell Neoplasm, Glandular,Cell Neoplasms, Epithelial,Epithelial Cell Neoplasm,Epithelial Neoplasm,Epithelial Neoplasm, Glandular,Glandular Cell Neoplasm,Glandular Epithelial Neoplasm,Glandular Epithelial Neoplasms,Glandular Neoplasm,Neoplasm, Epithelial,Neoplasm, Epithelial Cell,Neoplasm, Glandular,Neoplasm, Glandular Cell,Neoplasm, Glandular Epithelial
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011506 Proteins Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein. Gene Products, Protein,Gene Proteins,Protein,Protein Gene Products,Proteins, Gene
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077216 Carcinoma, Ovarian Epithelial A malignant neoplasm that originates in cells on the surface EPITHELIUM of the ovary and is the most common form of ovarian cancer. There are five histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Mutations in BRCA1, OPCML, PRKN, PIK3CA, AKT1, CTNNB1, RRAS2, and CDH1 genes are associated with this cancer. Epithelial Ovarian Cancer,Epithelial Ovarian Carcinoma,Ovarian Cancer, Epithelial,Ovarian Epithelial Cancer,Ovarian Epithelial Carcinoma,Cancer, Epithelial Ovarian,Cancer, Ovarian Epithelial,Carcinoma, Epithelial Ovarian,Epithelial Cancer, Ovarian,Epithelial Carcinoma, Ovarian,Epithelial Ovarian Cancers,Epithelial Ovarian Carcinomas,Ovarian Carcinoma, Epithelial,Ovarian Epithelial Cancers,Ovarian Epithelial Carcinomas
D000081102 WAP Four-Disulfide Core Domain Protein 2 A secreted 25-kDa glycoprotein member of the Whey-acidic-protein (WAP) four-disulfide core (WFDC) domain family with tissue specific expression in the EPIDIDYMIS. It is also expressed in a limited number of other organs which include female reproductive tract, breast tissue, kidney, regions of the respiratory tract and nasopharynx. The protein is a biomarker for epithelial ovarian cancer. Epididymal Secretory Protein E4,WFDC2 Protein,Protein, WFDC2,WAP Four Disulfide Core Domain Protein 2

Related Publications

Sun-Young Kong, and Mi Hwa Han, and Heon-Jong Yoo, and Jong Ha Hwang, and Myong Cheol Lim, and Sang-Soo Seo, and Chong-Woo Yoo, and Jae-Hoon Kim, and Sang-Yoon Park, and Sokbom Kang
November 2014, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico,
Sun-Young Kong, and Mi Hwa Han, and Heon-Jong Yoo, and Jong Ha Hwang, and Myong Cheol Lim, and Sang-Soo Seo, and Chong-Woo Yoo, and Jae-Hoon Kim, and Sang-Yoon Park, and Sokbom Kang
September 2009, Journal of surgical oncology,
Sun-Young Kong, and Mi Hwa Han, and Heon-Jong Yoo, and Jong Ha Hwang, and Myong Cheol Lim, and Sang-Soo Seo, and Chong-Woo Yoo, and Jae-Hoon Kim, and Sang-Yoon Park, and Sokbom Kang
January 2015, PloS one,
Sun-Young Kong, and Mi Hwa Han, and Heon-Jong Yoo, and Jong Ha Hwang, and Myong Cheol Lim, and Sang-Soo Seo, and Chong-Woo Yoo, and Jae-Hoon Kim, and Sang-Yoon Park, and Sokbom Kang
November 2017, Archives of gynecology and obstetrics,
Sun-Young Kong, and Mi Hwa Han, and Heon-Jong Yoo, and Jong Ha Hwang, and Myong Cheol Lim, and Sang-Soo Seo, and Chong-Woo Yoo, and Jae-Hoon Kim, and Sang-Yoon Park, and Sokbom Kang
January 2000, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
Sun-Young Kong, and Mi Hwa Han, and Heon-Jong Yoo, and Jong Ha Hwang, and Myong Cheol Lim, and Sang-Soo Seo, and Chong-Woo Yoo, and Jae-Hoon Kim, and Sang-Yoon Park, and Sokbom Kang
August 2012, Gynecologic oncology,
Sun-Young Kong, and Mi Hwa Han, and Heon-Jong Yoo, and Jong Ha Hwang, and Myong Cheol Lim, and Sang-Soo Seo, and Chong-Woo Yoo, and Jae-Hoon Kim, and Sang-Yoon Park, and Sokbom Kang
November 2015, The International journal of biological markers,
Sun-Young Kong, and Mi Hwa Han, and Heon-Jong Yoo, and Jong Ha Hwang, and Myong Cheol Lim, and Sang-Soo Seo, and Chong-Woo Yoo, and Jae-Hoon Kim, and Sang-Yoon Park, and Sokbom Kang
January 2003, British journal of cancer,
Sun-Young Kong, and Mi Hwa Han, and Heon-Jong Yoo, and Jong Ha Hwang, and Myong Cheol Lim, and Sang-Soo Seo, and Chong-Woo Yoo, and Jae-Hoon Kim, and Sang-Yoon Park, and Sokbom Kang
January 1999, Cancer,
Sun-Young Kong, and Mi Hwa Han, and Heon-Jong Yoo, and Jong Ha Hwang, and Myong Cheol Lim, and Sang-Soo Seo, and Chong-Woo Yoo, and Jae-Hoon Kim, and Sang-Yoon Park, and Sokbom Kang
September 1997, Cancer,
Copied contents to your clipboard!